**AI生物标志物分析公司Nucleai完成1400万美元B+轮融资，引领医疗诊断新趋势**
以色列AI空间生物标志物分析初创公司Nucleai近日宣布，已成功获得1400万美元的B+轮融资，本次投资由知名风投公司M Ventures领投。Nucleai的现有投资者Section 32、Sanofi Ventures、Debiopharm、复星锐正资本、Vertex Ventures Israel和Grove Ventures等也积极参与了本轮融资。这一资金注入将助力Nucleai进一步推进其创新技术的研发和应用。
Nucleai专注于利用人工智能和机器学习技术，对细胞和组织层面的病理图像及空间数据进行深度分析，以预测疾病治疗效果，尤其是在医疗诊断领域展现出巨大潜力。这一技术的运用有望提高医疗决策的精准性和效率，为临床医生提供更可靠的信息支持。
本轮投资的领投方M Ventures表示，他们对Nucleai在AI驱动的生物标志物分析领域的创新能力和市场前景充满信心。Nucleai的解决方案不仅能够加速药物研发进程，还能为患者提供更个性化的治疗方案。
Nucleai的创始人兼首席执行官表示，这笔资金将用于扩大研发团队，优化其AI平台，并加速产品商业化进程，以满足全球医疗市场对精准医疗解决方案日益增长的需求。
随着人工智能在医疗领域的深入应用，Nucleai的创新技术有望重塑病理学研究和临床实践，为全球医疗健康行业带来革命性的变化。
英语如下：
**AI Biomarker Analysis Company Nucleai Closes $14M B+ Round, Pioneering a New Era in Pathological Image Intelligence**
Keywords: AI bioanalysis, Nucleai funding,病理 image analysis
**Israeli AI-based biomarker analysis startup Nucleai recently announced the successful completion of a $14 million B+ funding round, led by prominent venture capital firm M Ventures.** The round also saw participation from existing investors Section 32, Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, and Grove Ventures. This injection of funds will support Nucleai in further advancing its innovative technologies and applications.
Nucleai specializes in utilizing artificial intelligence and machine learning to perform in-depth analysis of病理 images and spatial data at the cellular and tissue level, predicting treatment outcomes in diseases, particularly showing great potential in medical diagnosis. The application of this technology aims to enhance the precision and efficiency of medical decision-making, providing clinicians with more reliable information.
M Ventures, the lead investor in this round, expressed confidence in Nucleai’s innovative capabilities and market prospects in the AI-driven biomarker analysis field. Nucleai’s solutions not only accelerate drug development but also enable more personalized treatment options for patients.
Nucleai’s founder and CEO stated that the funds will be used to expand the R&D team, optimize their AI platform, and accelerate the commercialization process to cater to the growing global demand for precision medical solutions.
With the increasing integration of AI in healthcare, Nucleai’s innovative technology is poised to revolutionize pathology research and clinical practice, bringing transformative changes to the global healthcare industry.
【来源】https://www.calcalistech.com/ctechnews/article/r11brac1a
Views: 5